Activation of Peroxisome Proliferator-Activated Receptor-β/δ (PPAR-β/δ) Inhibits Human Breast Cancer Cell Line Tumorigenicity

Peters, 2009, Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) in cell proliferation and cancer, Biochim Biophys Acta, 1796, 230

Peters, 2008, Role of peroxisome-proliferator-activated receptor β/δ (PPAR-β/δ) in gastrointestinal tract function and disease, Clin Sci, 115, 107, 10.1042/CS20080022

Peters, 2011, Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ), Drug Discov Today, 8, e85, 10.1016/j.ddmec.2011.11.002

Peters, 2012, The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention, Nat Rev Cancer, 12, 181, 10.1038/nrc3214

Khozoie, 2012, Analysis of the peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) cistrome reveals novel co-regulatory role of ATF4, BMC Genomics, 13, 665, 10.1186/1471-2164-13-665

Peters, 2011, Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) in colon, breast and lung carcinogenesis, Cancer Metastasis Rev, 30, 619, 10.1007/s10555-011-9320-1

Girroir, 2008, Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) protein in mice, Biochem Biophys Res Commun, 371, 456, 10.1016/j.bbrc.2008.04.086

Kilgore, 2008, PPAR-β/δ ligands as modulators of the inflammatory response, Curr Opin Investig Drugs, 9, 463

Grimaldi, 2010, Metabolic and nonmetabolic regulatory functions of peroxisome proliferator-activated receptorβ, Curr Opin Lipidol, 21, 186, 10.1097/MOL.0b013e32833884a4

Stephen, 2004, Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines, Cancer Res, 64, 3162, 10.1158/0008-5472.CAN-03-2760

Aung, 2006, Isoform specific changes in PPAR-α and β in colon and breast cancer with differentiation, Biochem Biophys Res Commun, 340, 656, 10.1016/j.bbrc.2005.12.061

Buttitta, 2007, Mechanisms controlling cell cycle exit upon terminal differentiation, Curr Opin Cell Biol, 19, 697, 10.1016/j.ceb.2007.10.004

Girroir, 2008, Peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines, Toxicology, 243, 236, 10.1016/j.tox.2007.10.023

Palkar, 2010, Cellular and Pharmacological Selectivity of the PPAR-β/δ Antagonist GSK3787, Mol Pharmacol, 78, 419, 10.1124/mol.110.065508

Ghosh, 2009, PPAR-δ is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer, Prostaglandins Other Lipid Mediat, 88, 97, 10.1016/j.prostaglandins.2008.11.004

Yin, 2005, Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis, Cancer Res, 65, 3950, 10.1158/0008-5472.CAN-04-3990

Yuan, 2013, PPAR-δ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mtor activation, Cancer Res, 73, 4349, 10.1158/0008-5472.CAN-13-0322

Foreman, 2010, Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits cell growth in a mouse mammary gland cancer cell line, Cancer Lett, 288, 219, 10.1016/j.canlet.2009.07.006

Pear, 1998, Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow, Blood, 92, 3780, 10.1182/blood.V92.10.3780

Borland, 2011, Stable over-expression of PPAR-β/δ and PPAR-γ to examine receptor signaling in human HaCaT keratinocytes, Cell Signal, 23, 2039, 10.1016/j.cellsig.2011.07.020

Foreman, 2011, Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer, Mol Carcinog, 50, 884, 10.1002/mc.20757

Borland, 2008, Ligand Activation of Peroxisome Proliferator-Activated Receptor-β/δ (PPAR-β/δ) Inhibits Cell Proliferation in Human HaCaT Keratinocytes, Mol Pharmacol, 74, 1429, 10.1124/mol.108.050609

Schug, 2008, Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPAR-β/δ to RAR, Proc Natl Acad Sci U S A, 105, 7546, 10.1073/pnas.0709981105

Tanaka, 2003, Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome, Proc Natl Acad Sci U S A, 100, 15924, 10.1073/pnas.0306981100

Nandhikonda, 2013, Peroxisome proliferation-activated receptor δ agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor, Biochemistry, 52, 4193, 10.1021/bi400321p

Graham, 2005, The PPAR-δ agonist GW0742X reduces atherosclerosis in LDLR−/− mice, Atherosclerosis, 181, 29, 10.1016/j.atherosclerosis.2004.12.028

Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093

Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98, 10869, 10.1073/pnas.191367098

Sorlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, 100, 8418, 10.1073/pnas.0932692100

Kiaris, 1999, Apoptosis versus necrosis: which should be the aim of cancer therapy?, Proc Soc Exp Biol Med, 221, 87, 10.3181/00379727-221-44388

Rieck, 2008, Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR-) β/δ: a comparative analysis of PPAR–selective agonists and all-trans retinoic acid, Mol Pharmacol, 74, 1269, 10.1124/mol.108.050625

Ma, 2009, Gene expression profiling of the tumor microenvironment during breast cancer progression, Breast Cancer Res, 11, R7, 10.1186/bcr2222

Uhlen, 2010, Towards a knowledge-based Human Protein Atlas, Nat Biotechnol, 28, 1248, 10.1038/nbt1210-1248